Back to top

gene-therapy: Archive

Zacks Equity Research

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.

RAREPositive Net Change CRMDNegative Net Change KNSANegative Net Change PHARPositive Net Change

Zacks Equity Research

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

EDIT nominates EDIT-401, a one-time in vivo gene editing therapy, as its lead pipeline candidate to cut the risk of elevated cholesterol.

CRMDNegative Net Change EDITPositive Net Change KNSANegative Net Change PHARPositive Net Change